Avidity Biosciences Inc. (RNA) News
Filter RNA News Items
RNA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RNA News Highlights
- RNA's 30 day story count now stands at 5.
- Over the past 19 days, the trend for RNA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- BIO and WMS are the most mentioned tickers in articles about RNA.
Latest RNA News From Around the Web
Below are the latest news stories about AVIDITY BIOSCIENCES INC that investors may wish to consider to help them evaluate RNA as an investment opportunity.
Avidity Biosciences Announces Upcoming Presentations at 28th Annual Congress of the World Muscle SocietyAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will be presenting one oral and six poster presentations at the 28th Annual Congress of the World Muscle Society (WMS), being held October 3-7, 2023, in Charleston, South Carolina. |
Avidity Biosciences to Participate in Upcoming Investor ConferencesAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating at the following upcoming conferences: |
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on September 20, 2023, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 90,300 shares of its common stock and 45,150 restricted stock units ("RSUs") to nine (9) new non-executive employees under the Avidity Bio |
Down More Than 50%: Analysts Say Buy These 2 Beaten-Down Stocks Before They ReboundEveryone likes a winner, and it’s only natural to gravitate toward them, but the stock market offers a unique twist on that process. That is because the biggest opportunities are often found among the losers, or more precisely, the stocks that have been beaten-down for one reason or another. The interesting part is that in the stock market, these losers can quickly become winners, and those who were bold enough to pick up equities at depressed levels when they looked down and out will, in the en |
Avidity Biosciences Joins with Patient Communities to Raise Awareness During National Muscular Dystrophy Awareness Month as it Advances Three Muscular Dystrophy Clinical ProgramsAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it is joining with patient communities to raise awareness during National Muscular Dystrophy Awareness Month, an annual observance that takes place every September to support families across the U.S. who are impacted by neuromuscular diseases. Today, Avidity will be joining Myotonic Dystrophy Foundati |
Avidity Biosciences Announces Upcoming Presentations at 2023 Myotonic Dystrophy Foundation Annual ConferenceAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will be presenting two poster presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, being held September 7-9, 2023, in Washington, D.C. |
Avidity Biosciences Receives FDA Orphan Drug Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 SkippingAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to AOC 1044, the company's investigational therapy in development for the treatment of Duchenne muscular dystrophy (DMD) in people with mutations amenable to exon 44 skipping (DMD44). DMD is a rare genetic condition that i |
Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Tops Revenue EstimatesAvidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of 21.43% and 11.08%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |
Avidity Biosciences Reports Second Quarter 2023 Financial Results and Recent HighlightsAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results and recent highlights for the second quarter ended June 30, 2023. Avidity ended the second quarter of 2023 with cash, cash equivalents and marketable securities totaling $577 million. |
Avidity Biosciences (NASDAQ:RNA) shareholders have endured a 59% loss from investing in the stock three years agoThe truth is that if you invest for long enough, you're going to end up with some losing stocks. But the last three... |